NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Intra-Cellular Therapies.

10 Wall Street analysts have issued 1 year target prices for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' share price to reach $37.75 in the next twelve months. This suggests a possible upside of 64.8% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

News articles about ITCI stock have trended somewhat negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a decrease of 21.9% from the January 15th total of 8,370,000 shares. Based on an average trading volume of 2,790,000 shares, the short-interest ratio is currently 2.3 days. Currently, 14.0% of the company's shares are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Crispr Therapeutics (CRSP), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Geode Capital Management LLC (1.15%) and Rhenman & Partners Asset Management AB (0.90%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Geode Capital Management LLC, General American Investors Co. Inc. and Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was bought by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, LMR Partners LLP, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates and Palo Alto Investors LP. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $22.90.

Intra-Cellular Therapies has a market capitalization of $1.27 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]